Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection

Citations Over TimeTop 13% of 2019 papers

Abstract

Adoptive transfer of TCR transgenic T cells holds great promise for treating various cancers. So far, mainly semi-randomly integrating vectors have been used to genetically modify T cells. These carry the risk of insertional mutagenesis, and the sole addition of an exogenous TCR potentially results in the mispairing of TCR chains with endogenous ones. Established approaches using nonviral vectors, such as transposons, already reduce the risk of insertional mutagenesis but have not accomplished site-specific integration. Here, we used CRISPR-Cas9 RNPs and adeno-associated virus 6 for gene targeting to deliver an engineered TCR gene specifically to the TCR alpha constant locus, thus placing it under endogenous transcriptional control. Our data demonstrate that this approach replaces the endogenous TCR, functionally redirects the edited T cells' specificity in vitro, and facilitates potent tumor rejection in an in vivo xenograft model.

Related Papers

• → Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio)(2018)99 cited
• → CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy(2018)53 cited
• → Targeted mutagenesis in Arabidopsis thaliana using CRISPR‐Cas12b/C2c1(2020)42 cited
• → A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells(2017)5 cited
• → A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells(2017)5 cited